Phase 1a/1b Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, CTRM-505 and DTRM-555, in Patients with Chronic Lymphocytic Leukemia or Other B-Cell Lymphomas

Administered By

Awarded By

Contributors

Start/End

  • February 28, 2018 - April 30, 2023